Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Pacific Biosciences of California Are Under Pressure Today

By Cory Renauer – Jan 11, 2022 at 1:13PM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Preliminary fourth-quarter results reached a record high but didn't quite meet expectations.

What happened

The stock of Pacific Biosciences of California (PACB 4.00%), a company developing DNA sequencing machines, is losing ground after an investor update. Preliminary fourth-quarter sales figures missed expectations, driving the stock 11.8% lower as of 12:54 p.m. ET on Tuesday.  

So what 

Preliminary sales figures from the fourth quarter weren't bad, but they were slightly less than the market was expecting. The average investment bank analyst covering Pacific Biosciences of California (or PacBio) was expecting $36.6 million in revenue. PacBio stock is falling today because the company reported unaudited fourth-quarter revenue that reached just $36 million.

Investor checking stocks on a computer and tablet.

Image source: Getty Images.

Compared to the prior-year period, revenue soared 33%. The company even placed 48 next-generation Sequel systems during the last three months of 2021, which was a new quarterly record.

Now what

The narrow miss probably doesn't warrant such a strong move to the downside. That said, shares of PacBio were trading at some very lofty valuations. Despite the recent losses, the genetic sequencing stock is still trading at around 24.3 times trailing sales.

To provide market-beating gains from its still-lofty valuation, PacBio needs to maintain its current growth rate for at least several more years. A recently expanded collaboration with Invitae (NVTA 0.78%) will help by giving the company a hand in the rapidly expanding field of blood-based cancer detection.

Cory Renauer owns Invitae. The Motley Fool owns and recommends Invitae. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.